Thursday, April 22, 2021
61.4 F
Fort Worth

Pfizer buys Array BioPharma

Pfizer is buying Array BioPharma for $11.4 billion in a

deal that will expand its cancer drug arsenal.

Array makes an advanced skin cancer

treatment and has a deep pipeline of

cancer drugs in development. The

Boulder, Colorado-based company

said last month that its

combination of the drugs Braftovi

and Mektovi, along with another

treatment, led to a significant

improvement in overall survival in late-stage

testing for some patients with colorectal cancer. The

company plans to submit results from

that study to U.S. regulators for

approval later this year.

Pfizer’s offer of $48 per share

represents a premium of 62

percent to the stock’s closing price

on Friday.

Pfizer, the biggest U.S. drugmaker by

revenue, expects the transaction to add to

earnings per share starting in 2022.

Get our email updates

Related Articles

Our Digital Sponsors

Stay Connected


Join Our Newsletter

Latest Articles